DJDavid Hebbelstrup Jensen

David Hebbelstrup Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Hebbelstrup Jensen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Christian von Buchwald

    Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Rigshospitalet, University of Copenhagen Copenhagen Denmark

    5 shared publications
  • Lena Specht

    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    3 shared publications
  • Christian Grønhøj

    Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark

    2 shared publications
  • Allan Bardow

    Department of Oral Medicine, School of Dentistry, University of Copenhagen, Copenhagen, Denmark

    1 shared publication
  • Amanda F. Carlander

    Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark

    1 shared publication
  • Anders Christensen

    Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Performance of an Oral Rinse Point-Of-Care Assay to aid in the diagnosis of Head and Neck Squamous Cell Carcinoma (HNSCC) in a High-Risk Danish Ear-Nose Throat (ENT) Clinic

    by David Hebbelstrup Jensen, Mads Klokker

    Objectives: Oral examination and biopsy are established methods for early detection of oral/oropharyngeal squamous cell carcinoma (OOSCC). The aim of the current study was to evaluate performance of a point-of-care (POC) assay to aid in the diagnosis of head and neck cancer. Materials and methods: 150 consecutive patients were enrolled from a high-risk ear nose and throat clinic at the Rigshospitalet in Copenhagen, Denmark. A positive POC test represented as a CD44 band or elevated level of total protein (TP) was correlated with biopsy results and then evaluated with sensitivity (Se), specificity (Sp), PPV, NPV and multivariate models. Results: 119 patients enrolled between January 2016 and April 2017. Presence of a CD44 band or TP ≥3: Se of 73% (95% CI 57.0–84.6%), Sp of 50% (95% CI 39.4–60.5%), and NPV of 94.77% (95% CI 84.12–98.33%). CD44 band or TP of ≥ 2 for non-smkers and ≥ 3 for smokers improved performance: Se 81% (95%CI 66–90%) and Sp 33% (95%CI 24–44%), NPV of 94%. Multivariate models with male gender and ≥ 60 years: Se of 84% (95%CI 67–92%) and Sp of 37% (95%CI 27–47%), NPV of 95%. Non-biopsied, healthy, non-smoking, females (n = 17): Sp of 78%. Conclusions: POC assay performed well for identifying OOSCC in a prospective clinical trial. Clinical features such as age, smoking status and gender are important variables in assessing risk. Additional studies are underway to further confirm these results including the incorporation of a version 2 POC device.


  • Open Access

    The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022

    by Olivia Fruergaard, Mathias Ørholt, Peter Viktor Vester-Glowinski, David Hebbelstrup Jensen


  • The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    by Martin Zamani, Christian Grønhøj, David H. Jensen, Amanda F. Carlander, Tina Agander, Katalin Kiss, Caroline Olsen, Louise Baandrup, Finn C. Nielsen, Elo Andersen, et al.


  • Open Access

    Incidence and survival of oropharyngeal cancer in Denmark: a nation-wide, population-based study from 1980 to 2014

    by Jakob Schmidt Jensen, David Hebbelstrup Jensen, Christian Grønhøj, Kirstine Kim Schmidt Karnov, Cecilie Nørregaard, Tina Klitmøller Agander, Lena Specht, Christian von Buchwald


  • Open Access

    Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

    by Anders Christensen, Katalin Kiss, Giedrius Lelkaitis, Karina Juhl, Morten Persson, Birgitte Wittenborg Charabi, Jann Mortensen, Julie Lyng Forman, Anne Lyngholm Sørensen, David Hebbelstrup Jensen, et al.

    Tumor-specific biomarkers are a prerequisite for the development of targeted imaging and therapy in oral squamous cell carcinoma (OSCC). urokinase-type Plasminogen Activator Receptor (uPAR), Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR) are three biomarkers that exhibit enhanced expression in many types of cancers, and have been investigated as potential biomarkers for targeted strategies and prognostication. The aim of the study was to investigate the expression patterns of uPAR, TF and EGFR and their potential prognostic value in OSCC. Immunohistochemical expression of uPAR, TF and EGFR in tumor resection specimens from 191 patients with primary OSCC was analyzed. Overall (OS) and disease-free survival (DFS) was calculated. Associations between biomarker expression, clinicopathological factors and patient survival was analyzed using the Cox proportional hazards model for univariate and multivariate analysis, log rank and Kaplan-Meier statistics. uPAR and TF exhibited a highly tumor-specific expression pattern while EGFR also showed expression in normal tissues outside the tumor compartment. The overall positive expression rate of uPAR, TF and EGFR was 95%, 58% and 98%, respectively. High uPAR expression across the entire cohort was negatively associated with OS (p = 0.031, HR = 1.595 (95%CI 1.044–2.439)) in univariate analysis. The 5-year OS for high and low uPAR expression was 39% and 56%, respectively. The expression of TF and EGFR was not associated with survival outcome. This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. uPAR seems to be a prognostic biomarker in oral cancer.


  • Single cell migration in oral squamous cell carcinoma – possible evidence of epithelial–mesenchymal transition in vivo

    by David H. Jensen, Jesper Reibel, Ian C. Mackenzie, Erik Dabelsteen

    Background: The invasion of cancer cells into the surrounding normal tissue is one of the defining features of cancer. While the phenomena of tumour budding, epithelial–mesenchymal transition and the presence of myofibroblasts have independently been shown to be related to a poor prognosis of oral carcinomas, their relationship has not been examined in detail.Methods: Paraffin‐embedded tissues from 28 patients with oral squamous cell carcinomas were stained with antibodies to cytokeratin, α‐SMA, vimentin, E‐cadherin, N‐cadherin and Twist and evaluated for their expression in relation to invasive cancer cells and the surrounding tumour stroma.Results and conclusions: A direct, histological relationship between invading, budding tumour cells and myofibroblasts was occasionally seen but was not a general feature. Most of the budding tumour cells at the invasive front had a decreased expression of E‐cadherin, but we did not find that this was associated with a consistent or clear increase in either N‐cadherin or vimentin. We therefore suggest that the budding of tumour cells is not dependent upon either myofibroblasts or a complete epithelial–mesenchymal transition and that these phenomena most likely represent separate processes in tumour progression.


  • A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts

    by David H. Jensen, Marianne H. Therkildsen, Erik Dabelsteen

    Background: The reverse Warburg effect describes the phenomenon that epithelial cancer cells take advantage of the metabolic machinery from nearby cancer‐associated fibroblast, inducing them to produce lactate and ketones to fuel the high metabolic demands of the epithelial tumour tissues. This is in breast cancer observed as a lack of stromal caveolin‐1 (CAV‐1) and an increased expression of monocarboxylate transporter 4 (MCT‐4) in the tumour stroma, with a concomitant increase in the expression of monocarboxylate transporter 1 (MCT‐1) in the epithelial, tumour compartment. The lack of CAV‐1 and increased expression of MCT‐4 have been shown to have prognostic importance, primarily in patients with breast cancer. However, this phenomenon has only scarcely been described in oral squamous cell carcinoma (OSCC). Given the prognostic importance of myofibroblasts in OSCC, we also examined a potential relationship between the expression of MCT‐4 and the presence of myofibroblasts.Methods: Paraffin‐embedded tissues from 30 patients with OSCC were immunostained with antibodies towards MCT‐1, MCT‐4, Cav‐1, GLUT‐1, α‐SMA, TOMM20 and KI‐67, and evaluated for their specific epithelial and stromal expression.Results and conclusions: In patients with OSCC, we find an increased expression of MCT‐1 and MCT‐4 in both the epithelial and stromal compartment, with almost no overlap in their spatial expression. We found a large spatial overlap between α‐SMA and MCT‐1 in the stroma compartment, but no relationship between MCT‐4 and myofibroblasts. Interestingly, we did not observe any relationship between the absence of CAV‐1 and the presence of MCT‐4 as has been shown in breast carcinomas.


  • Open Access

    Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival

    by David Hebbelstrup Jensen, Nora Hedback, Lena Specht, Estrid Høgdall, Elo Andersen, Marianne Hamilton Therkildsen, Lennart Friis-Hansen, Bodil Norrild, Christian von Buchwald

    The purpose of this study was to examine the prevalence of human papillomavirus (HPV) in patients with head and neck squamous cell carcinoma of unknown primary (CUP). All patients diagnosed with and treated for CUP between January 1, 2000, and June 1, 2011, at two Danish medical centers were included. All patients received a thorough diagnostic work-up, including FDG-PET, before being diagnosed as CUP. We determined the HPV status in all patients using a combination of HPV DNA PCR and p16 stain. In addition, clinical information on the study patients was retrieved from clinical records. Of the identified 60 patients with CUP, 13 were shown to be positive for HPV DNA, amounting to 22% of the study population. In addition, we were able to show a clear disease-free and overall-survival benefit in the HPV-positive group, with a hazard ratio of 0.16 (95% CI: 0.038–0.67) for over-all survival. This survival benefit was also apparent when adjusted for advanced age in a multivariate Cox regression analysis. A fairly large percentage of CUP cases are HPV-related, and because this is related to both the location and prognosis, we recommend HPV testing as part of the diagnostic work-up.


  • Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies

    by David Hebbelstrup Jensen, Roberto Stefan Oliveri, Stig-Frederik Trojahn Kølle, Anne Fischer-Nielsen, Lena Specht, Allan Bardow, Christian Buchwald